Guerbet S. A. - Asset Resilience Ratio
Guerbet S. A. (GBT) has an Asset Resilience Ratio of 3.05% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Guerbet S. A.'s working capital to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2025)
This chart shows how Guerbet S. A.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Guerbet S. A. assets under control.
Liquid Assets Composition Over Time
This chart breaks down Guerbet S. A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore GBT long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €28.33 Million | 3.05% |
| Total Liquid Assets | €28.33 Million | 3.05% |
Asset Resilience Insights
- Limited Liquidity: Guerbet S. A. maintains only 3.05% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Guerbet S. A. Industry Peers by Asset Resilience Ratio
Compare Guerbet S. A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Medtronic plc
SA:MDTC34 |
Medical Devices | 7.82% |
|
Demant A/S
CO:DEMANT |
Medical Devices | -2.59% |
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Medartis Holding AG
SW:MED |
Medical Devices | 0.00% |
|
Xiangyu Medical Co. Ltd. A
SHG:688626 |
Medical Devices | 1.53% |
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
Beijing Chunlizhengda Medical Instruments Co Ltd
SHG:688236 |
Medical Devices | 25.01% |
|
Mediantechn
PA:ALMDT |
Medical Devices | 0.45% |
Annual Asset Resilience Ratio for Guerbet S. A. (2004–2025)
The table below shows the annual Asset Resilience Ratio data for Guerbet S. A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 3.05% | €28.33 Million ≈ $33.12 Million |
€930.02 Million ≈ $1.09 Billion |
-0.44pp |
| 2024-12-31 | 3.49% | €36.17 Million ≈ $42.29 Million |
€1.04 Billion ≈ $1.21 Billion |
-0.56pp |
| 2023-12-31 | 4.05% | €41.48 Million ≈ $48.50 Million |
€1.03 Billion ≈ $1.20 Billion |
-0.34pp |
| 2022-12-31 | 4.38% | €41.17 Million ≈ $48.13 Million |
€939.64 Million ≈ $1.10 Billion |
+0.10pp |
| 2021-12-31 | 4.29% | €42.90 Million ≈ $50.15 Million |
€1.00 Billion ≈ $1.17 Billion |
+0.78pp |
| 2020-12-31 | 3.51% | €33.15 Million ≈ $38.76 Million |
€945.71 Million ≈ $1.11 Billion |
-0.07pp |
| 2019-12-31 | 3.57% | €36.04 Million ≈ $42.13 Million |
€1.01 Billion ≈ $1.18 Billion |
-0.89pp |
| 2018-12-31 | 4.46% | €48.22 Million ≈ $56.38 Million |
€1.08 Billion ≈ $1.26 Billion |
-0.48pp |
| 2017-12-31 | 4.94% | €47.09 Million ≈ $55.06 Million |
€953.59 Million ≈ $1.11 Billion |
+4.84pp |
| 2016-12-31 | 0.10% | €1.03 Million ≈ $1.21 Million |
€1.03 Billion ≈ $1.20 Billion |
-0.01pp |
| 2015-12-31 | 0.11% | €975.00K ≈ $1.14 Million |
€902.50 Million ≈ $1.06 Billion |
+0.03pp |
| 2014-12-31 | 0.08% | €361.00K ≈ $422.05K |
€475.63 Million ≈ $556.07 Million |
-0.03pp |
| 2013-12-31 | 0.11% | €494.00K ≈ $577.54K |
€459.55 Million ≈ $537.26 Million |
+0.06pp |
| 2012-12-31 | 0.05% | €239.00K ≈ $279.42K |
€460.97 Million ≈ $538.92 Million |
-7.18pp |
| 2008-12-31 | 7.23% | €27.69 Million ≈ $32.37 Million |
€382.96 Million ≈ $447.72 Million |
+7.29pp |
| 2006-12-31 | -0.06% | €-192.00K ≈ $-224.47K |
€326.51 Million ≈ $381.72 Million |
+0.03pp |
| 2005-12-31 | -0.09% | €-268.00K ≈ $-313.32K |
€295.81 Million ≈ $345.84 Million |
+0.00pp |
| 2004-12-31 | -0.09% | €-235.00K ≈ $-274.74K |
€255.67 Million ≈ $298.91 Million |
-- |
About Guerbet S. A.
Guerbet SA provides a range of contrast media, medical devices, and digital and AI solutions for diagnostic and interventional imaging worldwide. It offers DOTAREM, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced MRI examinations; Elucirem, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced resonance imaging; UNIK, a diagnostic imaging interconne… Read more